Figures
- Figure 1.
Definition of a morbidity/mortality event: primary end-point used in the SERAPHIN trial. PAH: pulmonary arterial hypertension; 6MWD: 6-min walk distance; WHO FC: World Health Organization functional class; RHF: right heart failure; PDE-5i: phosphodiesterase-5 inhibitor; ERA: endothelin receptor antagonist.
- Figure 2.
Change in pulmonary vascular resistance (PVR) from baseline to week 17 in a randomised, placebo-controlled phase II trial of selexipag in patients with pulmonary arterial hypertension. Data are presented as geometric means with 95% confidence intervals. #: Wilcoxon rank sum test. Reproduced from [37] with permission from the publisher.
Vol 20 Issue 122
Table of Contents
Looking to the future: a new decade of pulmonary arterial hypertension therapy
